CNAT News Alert Conatus Pharmaceuticals Inc (CNAT) 10.63 01/06/2015

New Post Public Reply Private Reply Replies (0) Message Board

Jan 6, 2015 at 6:28 PM

Conatus Pharmaceuticals Inc (CNAT) 10.63 $CNAT

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - 53 mins ago

NGL: 26.51 (+0.19), BXS: 20.85 (-0.60), CFR: 65.85 (-1.65), AEM: 29.03 (+1.58), CNAT: 10.63 (+0.57), JCP: 6.56 (+0.12), AXTA: 27.71 (+1.03), SN: 8.39 (+0.05), WIFI: 7.48 (-0.17), OZRK: 34.67 (-1.08)

Is Conatus Poised For A Breakout?
Left Banker - at Seeking Alpha - Tue Jan 06, 1:42PM CST

CNAT: 10.63 (+0.57), PFE: 31.42 (+0.26)

Medtronic's (MDT) IN.PACT Admiral DCB Wins FDA Go-Ahead - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 1:40PM CST
Medtronic's (MDT) IN.PACT Admiral DCB helps in reopening narrowed or blocked arteries located in the upper leg of a peripheral artery disease (PAD) patient.
ICUI: 80.48 (-0.09), BCR: 165.56 (+0.57), MDT: 71.22 (-0.36), CNAT: 10.63 (+0.57)

Zimmer Holdings Scales 52-Week High on Portfolio Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 12:55PM CST
With the grand $13.35 billion acquisition of Biomet, Zimmer (ZMH) expects to create a market leader in the $45 billion musculoskeletal industry
ZMH: 115.80 (-0.99), ICUI: 80.48 (-0.09), INSY: 43.04 (+0.32), CNAT: 10.63 (+0.57)

Stryker Acquires Assets of Canada-based CHG Hospital Beds - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 12:30PM CST
The all-cash deal is expected to be neutral to Stryker Corporation's (SYK) 2015 earnings per share, barring acquisition, integration-related and intangible amortization charges and accretive thereafter.
ICUI: 80.48 (-0.09), SNN: 35.90 (+0.02), CNAT: 10.63 (+0.57), SYK: 92.41 (-0.13)

Gilead Acquires Drug Program For Fatty Liver Disease
at Investor's Business Daily - Tue Jan 06, 10:20AM CST
Big-cap biotech Gilead Sciences (GILD) agreed Tuesday to acquire a program from small German biotech Phenex Pharmaceuticals aimed at treating liver disease. Gilead agreed to an unspecified upfront payment and milestone payments totaling up to $470...
RPTP: 10.28 (-0.33), GILD: 97.65 (+0.86), CNAT: 10.63 (+0.57), ICPT: 160.01 (-16.99), FGEN: 35.06 (+1.27)

IPO Stock Watch: FibroGen Up With Liver-Disease Field
at Investor's Business Daily - Mon Jan 05, 3:40PM CST
Biotech FibroGen (FGEN) jumped 23% Monday to 33.83, a new high for a stock that went public at 18 on Nov. 13. FibroGen stock rose along with several other players in the liver-disease field, including Intercept Pharmaceuticals (ICPT), Conatus (CNAT)...
RPTP: 10.28 (-0.33), CNAT: 10.63 (+0.57), ICPT: 160.01 (-16.99), FGEN: 35.06 (+1.27)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 11:48AM CST

SD: 1.41 (-0.12), XENT: 20.23 (-0.50), WLL: 29.40 (-0.34), BTE: 14.21 (-0.50), BOTA: 2.65 (-0.20), CNAT: 10.63 (+0.57), WG: 5.40 (+0.01), SN: 8.39 (+0.05), LPI: 8.42 (-0.95), EROC: 2.16 (-0.04), BCLI: 5.00 (-0.75), NDRM: 15.45 (+1.80), SMLR: 2.69 (+0.34), QURE: 17.23 (+0.07), SFY: 3.23 (+0.07), ANTH: 2.20 (-0.07), PLX: 2.02 (-0.15), APRI: 1.31 (-0.03), STXS: 1.70 (-0.18), GST: 2.14 (-0.14)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 8:10AM CST

CERS: 5.78 (-0.79), E: 32.08 (+0.12), SSL: 34.64 (-0.36), CNAT: 10.63 (+0.57), SDRL: 10.48 (-0.33), NBG: 1.58 (-0.08), BCLI: 5.00 (-0.75), URZ: 1.20 (+0.02), PBR: 6.02 (-0.05), ISIS: 65.44 (-2.73), KITE: 71.45 (+1.70), PLX: 2.02 (-0.15), CEMP: 23.15 (-1.40), STXS: 1.70 (-0.18)

Conatus up big premarket
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 7:31AM CST

CNAT: 10.63 (+0.57)

Conatus to report results from three clinical trials on Thursday
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 6:27AM CST

CNAT: 10.63 (+0.57)

Conatus to Report Top-line Results From ACLF and Organ Impairment Clinical Trials of Emricasan
GlobeNewswire - Mon Jan 05, 6:23AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report top-line results from three clinical trials in subjects with varying degrees of organ impairment - the company's Phase 2 trial in patients with acute-on-chronic liver failure (ACLF), Phase 1 trial in patients with mild, moderate and severe hepatic impairment, and Phase 1 trial in patients with severe renal impairment - after the market close on Thursday, January 8, 2015. Conatus will host a conference call and webcast with an associated presentation at 4:30 p.m. Eastern Time on Thursday, January 8, 2015, to discuss the trial results.
CNAT: 10.63 (+0.57)

The 2015 Calendar Of NASH Trial Catalysts Series Brings Huge Opportunities For Investors
Clinically Sound Investor - at Seeking Alpha - Fri Dec 19, 2:29AM CST

RPTP: 10.28 (-0.33), CNAT: 10.63 (+0.57)

Conatus Pharmaceuticals: A Potential Double Worth Consideration
Bret Jensen - at Seeking Alpha - Sat Dec 13, 1:23PM CST

CNAT: 10.63 (+0.57)

Conatus Pharmaceuticals to Present at Two December Investor Conferences
GlobeNewswire - Mon Nov 24, 6:01AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced its scheduled participation in two upcoming investor conferences. The company is scheduled to participate in a "fireside chat" discussion with the covering research analyst at the 26th Annual Piper Jaffray Health Care Conference at 3:30 p.m. ET on Tuesday, December 2, 2014, in New York. The company is scheduled to deliver a formal presentation at the Oppenheimer 25th Annual Healthcare Conference at 11:30 a.m. ET on Wednesday, December 10, 2014, in New York.
CNAT: 10.63 (+0.57)

European Ad Comm gives thumbs up to AbbVie's HCV combo
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 7:48AM CST

GILD: 97.65 (+0.86), ACHN: 12.81 (-0.51), CNAT: 10.63 (+0.57), MRK: 60.32 (+2.28), RGLS: 15.68 (-0.56), ABBV: 64.33 (-0.32), BMY: 58.48 (-0.10), ENTA: 48.88 (-1.04)

2 Attractive But Speculative Biotech Gems For Consideration
Bret Jensen - at Seeking Alpha - Fri Nov 14, 8:17AM CST

AGEN: 3.91 (-0.26), CNAT: 10.63 (+0.57)

Conatus Pharmaceuticals' (CNAT) CEO Steven Mento on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 7:05PM CST

CNAT: 10.63 (+0.57)

Conatus Pharmaceuticals beats by $0.02
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:04PM CST

CNAT: 10.63 (+0.57)

Conatus Pharmaceuticals Reports Third Quarter 2014 Financial Results and Program Updates
GlobeNewswire - Wed Nov 12, 3:02PM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the quarter and nine months ended September 30, 2014, and provided updates on its clinical development programs.
CNAT: 10.63 (+0.57)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Streamlined AI Video Analytics for Public Safety Unveiled

AI Without the Headache Alright folks, IREX is shaking things up, and not in the usual iterative, bit-by-bit tech progression way. StreamVLM™ has been rolled out as the world's first vision-language model (VLM) analytics engine tailored for the public safety sector—specifically, for cloud platforms. I’ve been around the block enough times to spot a significant shift...

USFCR Wins 2026 Award for Federal Contracting Services

Award-Winning Federal Contracting Strategies News from Clearwater, Florida: US Federal Contractor Registration (USFCR) just bagged the 2026 nod from Gov Business Review as the Federal Contracting Services of the Year. Now that's a feather in the cap worth talking about. This isn't some hallway compliment, folks. It's a signal that they've nailed how to get businesses...

Moore Law Investigates Aardvark Therapeutics' Risks

Moore Law Launches Probe Into Aardvark Therapeutics Nobody likes stumbling across bad news over their morning coffee, but sometimes the market loves to keep you on your toes. Now it's Aardvark Therapeutics (NASDAQ: AARD) in the headlines, and not how they'd like. This time, Moore Law PLLC is rolling up its sleeves to dig into potential misconduct by the company's top...

Americas Cardroom's Poker Series Hits $7.2M Haul

Massive Prize Pools Emerge in Just Four Days I found myself eyeballing some jaw-dropping numbers from Americas Cardroom's latest poker series, the Online Super Series XL. It's not every day you see nearly a hundred tournaments rake in over $7.2 million in prize pools in just four days. From September 6th to 9th, a whopping 62,847 entries signed up to make an honest...

Step Inside Henson's Creature Shop Magic in NYC

Unlock Puppet Magic with Jim Henson Tours Puppet fans, let me tell you, there's something going on in Queens, NY that's got both nostalgia and innovation scribbled all over it. We're talking about the legendary Jim Henson's Creature Shop opening its doors. If you're looking to relive the magic that helped shape a generation, get ready to dive into a world where creativity...

Melissa Rivers Brings Her Wit Back to Emmys Carpet

They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...

XKL Delivers MediaLight for High-Speed Optical Transport

Unpacking the MediaLight Launch Kicking off September, XKL is tossing its hat in the ring with the MediaLight Xponder and Muxponder systems. These aren't just any run-of-the-mill gizmos—nope, they're touted as top-of-the-line optical transport solutions. The talk of the town is their ability to dish out high-density 100G and 400G transport, and for geeks in the trade,...

DCM Services Teams with AKUVO to Boost Estate Recoveries

Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...

NYSE Reflects on 9/11: Honoring Lives and Legacy

A Somber Day at NYSE: Reflecting on 9/11 September 11th grips the heart of NYSE every year, but this year's 25th-anniversary powerfully reverberates through its hallowed halls. The hustle of the trading floor halts for a moment at 9:20 AM ET, paying homage to those lost in the harrowing attacks. I've seen the markets flap in the wind of countless crises, but nothing's...

Intus Bio Secures $2.7M for Colorectal Cancer Test

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...